A Comparative Controlled Trial of Methotrimeprazine (“Veractil”) in Chronic Schizophrenia

Quinn, Patrick; Johnston, Jermaine G.; Latner, G.; Kiloh, L. G.

doi:10.1192/bjp.106.442.160

“…In addition...” (Atre-Vaidya and Jampala 1988 , 55). On the other hand, although structured as assertive in vocabulary and syntax, they are limited in their illocutionary force by means of conjunctions, adjectives and adverbs, presentation of the limits of current research, argumentation for “exception” (“DESPITE the good results [...] Nevertheless, the overall situation”, Quinn et al 1960 160). These mitigation proposals produce, as a general effect, the support of problematization and the complexity of the scenario, sometimes explicitly explained, especially when the intersection between physical and mental, scientific and moral aspects is touched (e.g.…”

Section: Resultsmentioning

confidence: 99%

Un-Certainty as a Pragmatic Resource for Psychiatric Argumentation: a Diachronical and Diatextual Approach

Scardigno

¹

,

Mininni

²

2020

Integr. psych. behav.

2

0

View full text Add to dashboard Cite

Psychiatry is the science that aims to propose plausible theories in the description and explanation of "body-mind" pathologies. Since also the modern institution of science produces a type of discourse aimed at reducing human insecuritas through a progressive falsification of conjectures on how things are actually, it seems very important to monitor the discursive construction of uncertainty about an extremely elusive object such as the abnormality of psychic functioning. In the light of this, the present paper aims to identify what changes are traceable in the argumentative structure of uncertainty in the psychiatric scientific communication by the British Journal of Psychiatry in its life span as well as how the construction of socially "credible" authorship profiles evolves. The randomly-selected 90 articles from the 160 years of the BJP life cycle were analyzed through various interpretative apparatuses, by practicing both bottom-up and top-down approaches. Indeed, in the perspective of cultural and discursive psychology, uncertainty is a multidimensional discursive construction which is not attributable to the psycho-linguistic level of the utterance in its entirety, but to the meta-pragmatic dimension of enunciation. The identified rhetoric, which collects the groupings of enunciative profiles, sees the researcher evolving between the explorer's attempts, the investigator's inquiries and the critical rigor of the technician.

show abstract

Chlorpromazine versus placebo for schizophrenia

Thornley¹,

Rathbone

²

,

Ce

³

et al. 2003

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. Objectives To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. Search methods We searched the Cochrane Schizophrenia Group's Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. Selection criteria We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and nonaffective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care. Data collection and analysis We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50% of participants were lost to follow-up. Where continuous data were included, we analysed this data using mean difference (MD) with a 95% confidence interval. We used a fixed-effect model. Main results We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow-up (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No difference was found in relapse rates in the short, medium or long term over two years, although data were also heterogeneous. We found chlorpromazine provided a global improvement in a person's symptoms and functioning (n=1164, 14 RCTs, RR 0.71 CI 0.58 to 0.86). Fewer people allocated to chlorpromazine left trials early (n=1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78) compared with placebo. There are many adverse effects. Chlorpromazine is clearly sedating (n=1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45), it increases 1 Chlorpromazine versus placebo for schizophrenia (Review)

show abstract

Chlorpromazine versus placebo for schizophrenia

Adams

¹

,

Awad

²

,

Rathbone

³

et al. 2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. Objectives To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. Search methods We searched the Cochrane Schizophrenia Group's Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. Selection criteria We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and nonaffective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care. Data collection and analysis We independently inspected citations and abstracts, ordered papers, re-inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50% of participants were lost to follow-up. Where continuous data were included, we analysed this data using mean difference (MD) with a 95% confidence interval. We used a fixed-effect model. Main results We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow-up (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No difference was found in relapse rates in the short, medium or long term over two years, although data were also heterogeneous. We found chlorpromazine provided a global improvement in a person's symptoms and functioning (n=1164, 14 RCTs, RR 0.71 CI 0.58 to 0.86). Fewer people allocated to chlorpromazine left trials early (n=1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78) compared with placebo. There are many adverse effects. Chlorpromazine is clearly sedating (n=1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45), it increases 1 Chlorpromazine versus placebo for schizophrenia (Review)

show abstract

A Comparative Controlled Trial of Methotrimeprazine (“Veractil”) in Chronic Schizophrenia

Cited by 9 publications

References 10 publications

Un-Certainty as a Pragmatic Resource for Psychiatric Argumentation: a Diachronical and Diatextual Approach

Un-Certainty as a Pragmatic Resource for Psychiatric Argumentation: a Diachronical and Diatextual Approach

Chlorpromazine versus placebo for schizophrenia

Chlorpromazine versus placebo for schizophrenia

Contact Info

Product

Resources

About